Oramed Oral Insulin Shows Evidence For NASH Treatment

Oramed Pharmaceuticals Inc ORMP announced Phase 2 results from its trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes (T2D) patients with non-alcoholic steatohepatitis (NASH). 

The 12-week trial enrolled 32 patients (with 30 patients completed). It demonstrated that ORMD-0801 was safe and well tolerated at 8 mg twice daily dosing, meeting the primary endpoint of no difference in adverse events for ORMD-0801 compared to placebo.

The trial also evaluated the effectiveness of ORMD-0801 in reducing liver fat content over the 12-week treatment period by observing several independent measures. 

All the measurements showed a consistent clinically meaningful trend in favor of ORMD-0801.

The company awaits the top-line data from the Phase 3 trial of oral insulin for T2D, expected in January 2023.

Price Action: ORMP shares are up 1.49% at $8.87 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!